Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China-based ShangPharma and Harbour Antibodies have signed a collaborative licensing agreement that would enable ShangPharma to develop therapeutic antibody candidates using Harbour's transgenic mouse-based fully human antibody development technology.
Subscribe to our email newsletter
ShangPharma will use Harbour’s human immunoglobulin-gene transgenic mice in Shanghai facility to provide fully human antibody development services to its clients.
Licensed under the agreement to produce H2L2 IgG antibodies, the antibody technology comprises two heavy chains and two light chains, with fully human variable regions.
ShangPharma CEO Michael Xin Hui said the company will work with Harbour to introduce the antibody technology in China.
"We are proud that Harbour sees the value of our services and has chosen to draw upon the strength of ShangPharma’s biologics R&D capabilities," Hui added.
ShangPharma biologics vice president Chengbin Wu said the partnership is a step forward for both firms to develop therapeutic antibodies in China.
”We are excited to combine Harbour’s industry-leading technology with the strength of our research teams to develop medicines that have the potential to improve the quality of treatment for patients," Wu added.